Nicole Rieder-Praschak
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Continuous infusion [11C]-(+)-PHNO PET for measuring dopamine D2/3 receptor availability and amphetamine effects across the brain: Feasibility and test-retest reliability.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 06, 2026
Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.
Journal: Frontiers in psychiatry
Published: December 12, 2025
The role of esketamine in persistent long COVID with predominant psychiatric manifestations.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Published: December 24, 2024
The relationship between prefrontal cortex gray matter volume and subcortical dopamine release - an addendum.
Journal: Molecular psychiatry
Published: September 05, 2023
The dopaminergic basis of negative symptoms in schizophrenia: an addendum.
Journal: Molecular psychiatry
Published: August 13, 2023
Case report: Hyperactive delirium after a single dose of zolpidem administered additionally to psychopharmacotherapy including clozapine.
Journal: Frontiers in psychiatry
Published: April 11, 2023
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder.
Journal: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
Published: January 21, 2022
Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia.
Journal: NeuroImage. Clinical
Published: May 07, 2021
Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain.
Journal: NeuroImage
Published: May 05, 2020
On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study.
Journal: Translational psychiatry
Published: September 02, 2019
Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report.
Journal: The journal of ECT
Published: May 19, 2017
Last Updated: 09/26/2026